CAVE CREEK, AZ--(Marketwired - Nov 14, 2017) - Endexx Corporation (
One of Endexx's best-selling products is from its pet line, Phyto-Bites®, a CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. A multi-billion dollar market opportunity, CBD products are now popularized in treating animals with everything from anxiety to allergies, epilepsy and support for cancer treatments, and FOX news recent coverage highlighted the increased treatments of medical marijuana for pet illnesses. For full coverage please visit: http://www.fox10phoenix.com/news/arizona-news...-illnesses
"What an honor it was to be awarded this prestigious title alongside many significant companies within the emerging hemp industry," said Todd Davis, CEO of Endexx. "We have made tremendous accomplishments over the past few quarters with our products launches and sales efforts, and look forward to another great year ahead."
The Uppie Awards are produced by Uptick Newswire, and its attendees include micro-cap investors, boutique hedge-fund managers, and other investors as well as local and national media outlets. Uptick Newswire utilized several metrics while narrowing down the final nominations for the Uppie Awards and selecting the winners. Factors such as how each company presented itself to the market in 2017 were considered, in addition to recent press release news. Detailed up-to-date financials, good standing on the OTC Markets, and company transparency also were taken into account. Other determining factors for choosing the winners in each category were company management, accessibility, and revenue growth. For more information please visit: https://upticknewswire.com/
About Endexx Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 -- the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and an "End of Sale" technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense™ is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com , www.endexx.com , www.phytobites.com .
See: www.C3globalbiosciences.com
Safe Harbor Notice This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Contact: For further investor and media information, contact: Endexx Corporation Todd Davis Chairman & CEO endexx@endexx.com 480-595-6900
